Roches Avastin for Ovarian Cancer Use

As a front-line (first-line following surgery) treatment for women with advanced ovarian cancer, the European Commission has approved Roche’s Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel).¬†Ovarian cancer is the most deadly of the gynecological cancers, with approximately 140,000 women dying from the disease each year globally. The approval of Avastin marks a Read more